Search

UT Southwestern researchers have discovered a molecular pathway that allows cells to sense when their lipid supplies become depleted, prompting a flurry of activity that prevents starvation. The findings, reported in Nature, might someday lead to new ways to combat metabolic disorders and a variety

The traditional lipid panel may not give the full picture of cholesterol-related heart disease risk for many Americans, according to a study led by UT Southwestern Medical Center researchers and published in JAMA Cardiology.

Whether you’re hosting summer backyard cookouts or escaping the heat with indoor gatherings, a nutrition expert at UT Southwestern Medical Center says there are lots of options for adding some nutrition to your plate.

ChatGPT, the artificial intelligence (AI) chatbot designed to assist with language-based tasks, can effectively extract data for research purposes from physicians’ clinical notes, UT Southwestern Medical Center researchers report in a new study.

Hip and knee replacements, sports injuries, trauma. That’s typically what comes to mind when one thinks of orthopedic surgery, not diabetes.

Roger H. Unger, M.D., a longtime Professor of Internal Medicine, a preeminent authority on glucagon and the development of diabetes, and the founding Director of the Touchstone Center for Diabetes Research at UT Southwestern Medical Center, died Aug. 22. He was 96.

A new cooling insole developed by UT Southwestern scientists reduced the foot temperature of patients with diabetic neuropathy by several degrees, diminishing a significant risk factor for diabetic foot ulcers.

Two genes working in tandem play a critical role in shaping the identity and behavior of prostate cancer cells and their response to treatment, UT Southwestern Medical Center researchers report.

– In a groundbreaking phase one clinical trial led by UT Southwestern Medical Center, a short interfering RNA (siRNA) drug directed to tumor cells, ARO-HIF2, effectively disrupted HIF2α, a key driver of clear cell renal cell carcinoma (ccRCC).

The number of mutations in the DNA of cancerous tumors may not be an indicator of how well patients will respond to immune checkpoint inhibitors (ICIs), a commonly prescribed type of immunotherapy, a team led by UT Southwestern Medical Center reported in a retrospective study.